French study suggests RSV monoclonal antibody offers only one season of protection for infants

While nirsevimab significantly reduces hospitalisations during the first RSV season, French researchers find its protective effect diminishes sharply by the following year, highlighting timing considerations for infant immunisation strategies. Babies given the RSV monoclonal antibody nirsevimab are much less likely…













